Author
Listed:
- Li Zhao
(Key Laboratory of AIDS Immunology of Ministry of Health, The First Affiliated Hospital, China Medical University
National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University)
- Shumei Wang
(Key Laboratory of AIDS Immunology of Ministry of Health, The First Affiliated Hospital, China Medical University
National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University)
- Meng Xu
(Research Institute for Cancer Therapy, The First Affiliated Hospital, China Medical University)
- Yang He
(Research Institute for Cancer Therapy, The First Affiliated Hospital, China Medical University)
- Xiaowei Zhang
(Key Laboratory of AIDS Immunology of Ministry of Health, The First Affiliated Hospital, China Medical University
National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University)
- Ying Xiong
(Key Laboratory of AIDS Immunology of Ministry of Health, The First Affiliated Hospital, China Medical University
National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University)
- Hong Sun
(Key Laboratory of AIDS Immunology of Ministry of Health, The First Affiliated Hospital, China Medical University
National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University)
- Haibo Ding
(Key Laboratory of AIDS Immunology of Ministry of Health, The First Affiliated Hospital, China Medical University
National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University)
- Wenqing Geng
(Key Laboratory of AIDS Immunology of Ministry of Health, The First Affiliated Hospital, China Medical University
National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University
Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences)
- Hong Shang
(Key Laboratory of AIDS Immunology of Ministry of Health, The First Affiliated Hospital, China Medical University
National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University
Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases)
- Guoxin Liang
(Key Laboratory of AIDS Immunology of Ministry of Health, The First Affiliated Hospital, China Medical University
National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University
Research Institute for Cancer Therapy, The First Affiliated Hospital, China Medical University
Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences)
Abstract
The HIV-1 accessory proteins Vif, Vpu, and Nef can promote infection by overcoming the inhibitory effects of the host cell restriction factors APOBEC3G, Tetherin, and SERINC5, respectively. However, how the HIV-1 accessory protein Vpr enhances infection in macrophages but not in CD4+ T cells remains elusive. Here, we report that Vpr counteracts lysosomal-associated transmembrane protein 5 (LAPTM5), a potent inhibitor of HIV-1 particle infectivity, to enhance HIV-1 infection in macrophages. LAPTM5 transports HIV-1 envelope glycoproteins to lysosomes for degradation, thereby inhibiting virion infectivity. Vpr counteracts the restrictive effects of LAPTM5 by triggering its degradation via DCAF1. In the absence of Vpr, the silencing of LAPTM5 precisely phenocopied the effect of Vpr on HIV-1 infection. In contrast, Vpr did not enhance HIV-1 infection in the absence of LAPTM5. Moreover, LAPTM5 was highly expressed in macrophages but not in CD4+ T lymphocytes. Re-expressing LAPTM5 reconstituted the Vpr-dependent promotion of HIV-1 infection in primary CD4+ T cells, as observed in macrophages. Herein, we demonstrate the molecular mechanism used by Vpr to overcome LAPTM5 restriction in macrophages, providing a potential strategy for anti-HIV/AIDS therapeutics.
Suggested Citation
Li Zhao & Shumei Wang & Meng Xu & Yang He & Xiaowei Zhang & Ying Xiong & Hong Sun & Haibo Ding & Wenqing Geng & Hong Shang & Guoxin Liang, 2021.
"Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages,"
Nature Communications, Nature, vol. 12(1), pages 1-14, December.
Handle:
RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-24087-8
DOI: 10.1038/s41467-021-24087-8
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-24087-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.